Daily Archives: June 18, 2021
Audio Interview: potential treatments for children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19.
18 Jun, 2021 | 08:33h | UTCAudio Interview: Covid-19 in Children – New England Journal of Medicine
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.
18 Jun, 2021 | 08:35h | UTCEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.
18 Jun, 2021 | 08:36h | UTCTreatment of Multisystem Inflammatory Syndrome in Children – New England Journal of Medicine
Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Commentaries: Steroids may be effective treatment for COVID-19 complications in children – Imperial College London AND Expert reaction to study looking at treatments for COVID-19 complications in children – Science Media Centre
Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.
18 Jun, 2021 | 08:29h | UTCCausation or confounding: why controls are critical for characterizing long COVID – Nature
Dr. Fauci says the risks from the Delta variant underscore the importance of vaccines.
18 Jun, 2021 | 08:31h | UTCDr. Fauci Says The Risks From The Delta Variant Underscore The Importance Of Vaccines – NPR
Cohort study: swallowing and voice outcomes in patients hospitalized with COVID-19.
18 Jun, 2021 | 08:24h | UTCRelated study: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One
ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.
18 Jun, 2021 | 08:26h | UTC
COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds.
18 Jun, 2021 | 08:27h | UTCOriginal study: Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing – Clinical Infectious Diseases
WHO: Caesarean section rates continue to rise, amid growing inequalities in access.
18 Jun, 2021 | 08:23h | UTCOriginal study: Trends and projections of caesarean section rates: global and regional estimates – BMJ Global Health
Commentary on Twitter (thread – click for more)
Caesarean section use continues to rise 📈 globally, now accounting for more than 1 in 5 of all childbirths.
C-section can put women and babies at unnecessary risk of short- and long-term health problems if performed when there is not medical need
— World Health Organization (WHO) (@WHO) June 17, 2021
Another meta-analysis supports aspirin withdrawal one to three months after percutaneous coronary intervention and continuation with P2Y12 inhibitor monotherapy.
18 Jun, 2021 | 08:22h | UTC
Study commentary: a history of hypothermia for cardiac arrest, 2002-2021 (RIP).
18 Jun, 2021 | 08:20h | UTCA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Original study: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Commentary on Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
RCT: Effects of intravenous Eptinezumab vs. placebo on headache pain and most bothersome symptom when initiated during a migraine attack.
18 Jun, 2021 | 08:16h | UTCEffects of Intraven.ous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary: Migraine Prevention Drug Eptinezumab Shows Efficacy in Treating Acute Attacks – Physician’s Weekly
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
M-A: Acute treatments for episodic migraine in adults.
18 Jun, 2021 | 08:18h | UTCAcute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (free for a limited period)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (free for a limited period)
Commentary on Twitter (thread – click for more)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information.
18 Jun, 2021 | 08:13h | UTC